1 11 C-LY2795050 is a novel kappa opioid receptor (KOR) antagonist tracer for positron emission tomography (PET) imaging. The purpose of this first-in-human study was to determine the optimal kinetic model for analysis of 11 C-LY2795050 imaging data. Sixteen subjects underwent baseline scans and blocking scans after oral naltrexone. Compartmental modeling and multilinear analysis-1 (MA1) were applied using the arterial input functions. Two-tissue compartment model and MA1 were found to be the best models to provide reliable measures of binding parameters. The rank order of 11 C-LY2795050 distribution volume (V T ) matched the known regional KOR densities in the human brain. Blocking scans with naltrexone indicated no ideal reference region for 11 C-LY2795050. Three methods for calculation of the nondisplaceable distribution volume (V ND ) were assessed: (1) individual V ND estimated from naltrexone occupancy plots, (2) mean V ND across subjects, and (3) a fixed fraction of cerebellum V T . Approach (3) produced the lowest intersubject variability in the calculation of binding potentials (BP ND , BP F , and BP P ). Therefore, binding potentials of 11 C-LY2795050 can be determined if the specific binding fraction in the cerebellum is presumed to be unchanged by diseases and experimental conditions. In conclusion, results from the present study show the suitability of 11 C-LY2795050 to image and quantify KOR in humans.
INTRODUCTION
The kappa opioid receptor (KOR) is one of the three major subtypes of opioid receptors. The distribution of KOR in human brain has been investigated in vitro with autoradiography, or radioligand binding assays using homogenized brain tissue. [1] [2] [3] [4] Kappa opioid receptor exists abundantly in amygdala, anterior cingulate cortex and insula, with moderate levels in the neocortical regions and putamen, followed by caudate, thalamus, globus pallidus, hippocampus, pons, and substantia nigra. Using reverse transcription-PCR detection of human KOR transcripts in human brain, 5 a signal was detected in most regions including the cerebellum. A low density of KOR was observed in cortex white matter by autoradiography using 3 H-U69593. 4 Multiple lines of evidence from preclinical and clinical studies have implicated KOR in a variety of neuropsychiatric disorders, including substance abuse, 6, 7 epilepsy, 8, 9 Alzheimer's disease 10, 11 and major depression. [12] [13] [14] As a result, considerable efforts have been made to develop radiotracers to image KOR in humans and probe its involvement in the pathophysiology of these disorders. A number of ligands have been developed, including 11 C-GR103545, 15 11 C-MeJDTic 16 and 11 C-LY2795050. 17 11 C-GR103545 is an agonist tracer extensively evaluated in nonhuman primates, [18] [19] [20] and recently in humans. 21 However, KOR agonists at relatively low mass doses elicit dysphoric 22 and psychomimetic 14 effects. Therefore, the use of agonist radiotracers in human positron emission tomography (PET) imaging requires careful control of the injected mass. On the other hand, KOR antagonists have been targeted for development as potential pharmacological agents for the treatment of a wide range of conditions such as drug addiction, depression, and feeding behavior, 23 and the application of antagonist radiotracers will make it possible to more easily perform KOR imaging in human. For antagonist tracers, 11 C-MeJDTic had high KOR affinity (K i = 1.01 ± 0.17 nmol/L; human cloned KOR) 24 and was evaluated in mice, 16 but no reports of its use in nonhuman primates or humans have been published. We have recently developed
In this paper, we present the results from our first-in-human study with the selective KOR antagonist 11 C-LY2795050. Our goals are (1) to determine the appropriate model to describe its in vivo kinetics and (2) to choose a suitable method to define the nondisplaceable distribution volume (V ND ) for derivation of binding potentials.
MATERIALS AND METHODS

Human Subjects
Sixteen healthy subjects (24 to 56 years of age; 8 men and 8 women, body weight 75 ± 10 kg) were included. Studies were performed under protocols approved by the Yale University School of Medicine Human Investigation Committee and the Yale-New Haven Hospital Radiation Safety Committee, and in accordance with the United States federal guidelines and regulations for the protection of human research subjects contained in Title 45 Part 46 of the Code of Federal Regulations (45 CFR 46). Written informed consent was obtained from all subjects. As part of the subject evaluation, magnetic resonance (MR) images were acquired on all subjects to eliminate those with structural brain abnormalities and for PET image registration. The MR imaging was performed on a 3-T whole-body scanner (Trio, Siemens Medical Systems, Erlangen, Germany) with a circularly polarized head coil. The dimension and pixel size of MR images were 256 × 256 × 176 and 0.98 × 0.98 × 1.0 mm 3 , respectively.
Radiotracer Synthesis 11 C-LY2795050 was synthesized as previously described. 17 Radiochemical purity of 11 C-LY2795050 in the final product solution was 499%.
Positron Emission Tomography Imaging Experiments
Subjects underwent two PET scans on the same day: a baseline 11 C-LY2795050 PET scan followed by a second scan at~75 minutes after an oral administration of 150 mg naltrexone, a nonselective opioid receptor antagonist. The time between tracer injections was 4.8 ± 0.9 hours. For one subject with 11 C-LY2795050, baseline and blocking scans were performed 1 month apart.
Positron emission tomography scans were conducted on the High Resolution Research Tomograph (HRRT) (Siemens Medical Solutions, Knoxville, TN, USA), which acquires 207 slices (1.2 mm slice separation) with a reconstructed image resolution (full width at half maximum) of 3 mm. Before tracer administration, a 6-minute transmission scan was conducted for attenuation correction. Each scan was acquired in list mode for 90 minutes after intravenous administration of tracer over 1 minute by an automatic pump (Harvard PHD 22/2000; Harvard Apparatus, Holliston, MA, USA). The injected mass limit was 10 μg. Dynamic scan data were reconstructed in 27 frames (6 × 0.5 minutes, 3 × 1 minutes, 2 × 2 minutes, 16 × 5 minutes) with corrections for attenuation, normalization, scatter, randoms, and deadtime using the MOLAR algorithm. 27 Event-by-event motion correction 28 was included in the reconstruction based on measurements with the Polaris Vicra sensor (NDI Systems, Waterloo, Canada) with reflectors mounted on a swim cap worn by the subject.
Input Function Measurement
For each subject, the radial artery was catheterized for blood sampling. An automated blood counting system (PBS-101; Veenstra Instruments, Joure, The Netherlands) was used to measure the radioactivity in whole blood during the first 7 minutes. Thirteen samples (2 to 10 mL) were collected manually at selected time points after tracer administration starting at 3 minutes. For each sample, plasma was obtained by centrifugation at 4°C (2,930 g for 5 minutes). Whole blood and plasma were counted in crosscalibrated gamma counters (1480 & 2480 WIZARD; Perkin-Elmer, Waltham, MA, USA).
To determine radioactivity in plasma for the first 7 minutes, the whole blood-to-plasma ratios were calculated from the hand-drawn samples. The ratio from 3 to 90 minutes was fitted to the following equation: at+b, and the plasma time-activity curve (TAC) in the first 7 minutes was calculated from the measured whole blood TAC and the extrapolated ratio. These data were combined with those from the plasma samples to produce the final curve of total radioactivity in plasma. To reduce noise in these data, the total plasma curve from~5 minutes onward was fitted to a sum of exponentials.
Plasma Metabolite Analysis
Analysis of the metabolite profile in the arterial plasma was performed using a modified automatic column-switching HPLC method. 29 Plasma samples collected at 5, 15, 30, 60, and 90 minutes after injection were mixed with urea (8 mol/L) and then filtered through 1.0 μm Whatman 13 mm GD/X syringe filters (GE, Florham Park, NJ, USA). Up to 5 mL of plasma filtrate was injected to the automatic HPLC system equipped with a Gemini-NX analytical column (4.6 × 250 mm, 5 μm; Phenomenex, Torrance, CA, USA) and eluted with a mobile phase consisting of 45% acetonitrile and 55% 0.1 mol/L ammonium formate (v/v) at a flow rate of 1.5 mL/min. The HPLC eluate was fraction-collected and counted in the gamma counters. The fraction counts were corrected for volume and decay. The unmetabolized parent fraction was calculated as the ratio of the sum of radioactivity in fractions containing the parent compound to the total amount of radioactivity collected, and fitted to an integrated gamma function (four fitted parameters: a, b, c, and d):
In addition, the time-varying extraction efficiency of radioactivity in filtered plasma samples was determined, and normalized to that of reference plasma sample. The plasma input function was calculated as the product of the total plasma activity, the parent HPLC fraction, and the normalized extraction efficiency.
Measurement of Tracer-Free Fraction in Plasma
Arterial blood samples were taken immediately before tracer injection for analysis of plasma-free fraction (f P ). An ultrafiltration (Millipore Centrifree micropartition device, 4104, Billerica, MA, USA) method was used for measuring f P of tracer in plasma in triplicate. The free fraction f P was determined from the count ratio of ultrafiltrate to plasma.
Image Registration and Definition of Regions of Interest
Regions of interest (ROIs) were taken from the AAL (Automated Anatomical Labeling) for SPM2 30 in MNI (Montreal Neurological Institute) space. 31 For each subject, the dynamic PET images after hardware motion correction were coregistered to the early summed PET images (0 to 10 minutes after injection) using a 6-parameter mutual information algorithm 32 (FLIRT of FSL) to eliminate any residual motion. The summed PET image was then coregistered to the subject's T1-weighted 3 T MR image (6-parameter rigid registration), which was subsequently coregistered to the AAL template in MNI space using a nonlinear transformation (Bioimage suite). 33 Using the combined transformations from template to PET space, regional TACs were generated for 14 ROIs: amygdala, caudate, centrum semiovale, cerebellum, anterior cingulate cortex, posterior cingulate cortex, frontal lobe, globus pallidus, hippocampus, insula, occipital lobe, putamen, temporal lobe, and thalamus.
Quantitative Analysis
Outcome measures were derived with kinetic analysis of the regional TACs using the arterial plasma TAC as an input function. The distribution volume (V T ) 34 was calculated using one-and two-tissue compartment models (1TC and 2TC), as well as the multilinear analysis-1 (MA1) method. 35 The time stability of V T estimates was evaluated by fitting the model to regional TACs with shortened scan durations, ranging from 90 to 30 minutes for 2TC, and from 90 to 50 minutes for MA1 (t* = 30 minutes) model. The ratio of V T value from the shortened scan to that from the 120-minute scan was computed for each ROI and duration. The following two criteria were used to determine a minimum scan duration 36 : (a) the average of the ratio was between 0.95 and 1.05; and (b) the interindividual standard deviation of the ratio was o0.1. The nondisplaceable distribution volume (V ND ) required for computing binding potentials was calculated from the occupancy plots (see below). The simplified reference tissue model (SRTM) with the cerebellum as a reference region was also applied to the regional TACs. Due to the lack of a suitable reference region, the estimated binding potential (BP ND ) values were corrected (see below). All modeling was performed with in-house programs written with IDL 8.0 (ITT Visual Information Solutions, Boulder, CO, USA). For parameter estimation, data points were weighted based on noise equivalent counts in each frame. Percentage standard error (%s.e.) was estimated from the theoretical parameter covariance matrix.
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The KOR occupancy (r) by naltrexone and nondisplaceable distribution volume (V ND ) were calculated from the following equation:
For each subject, the percentage of specific binding was calculated as the difference between V T and V ND divided by V T . All regions were used for the occupancy plots in the naltrexone blocking study, assuming uniform KOR occupancy. On the basis of the estimated V ND , the three binding potentials, BP ND , BP P and BP F were calculated using MA1-based V T estimates. The value of V ND was calculated in three ways: (1) individual V ND from each occupancy plot, (2) the mean V ND from all occupancy plots (i.e., a constant value for all subjects), and (3) the fraction of cerebellum V T corresponding to nonspecific binding. Approach (3) was used for both MA1 and SRTM models. Assuming that V T CER = αV ND (α is a constant value) in the pseudo reference tissue model, 38 the corrected BP ND is described as α(BP ND +1) − 1. The fraction value α was determined as the average ratio of the cerebellum V T to the V ND estimated from individual occupancy plots used in method (1) .
RESULTS
Injection Parameters
In the baseline and blocking scans, the subjects received radioactivity doses of 334 ± 149 MBq and 334 ± 152 MBq, respectively, with specific activity of 14.8 ± 6.5 GBq/μmol and 16.2 ± 6.8 GBq/μmol at the time of injection. Injections were performed by computer-controlled syringe pump. Injected mass was 9.3 ± 0.9 μg and 8.7 ± 2.1 μg for baseline and blocking scans, respectively. In most cases, the mass limit of 10 μg was the limiting factor, thus there was very little variability in the magnitude of injected mass.
Plasma Analysis
In either the baseline or blocking scan, total plasma activity stabilized at a constant level after 20 minutes after injection ( Figure 1A ).
11 C-LY2795050 metabolized fairly quickly in plasma ( Figure 1B) , with the parent fraction decreasing to 44 ± 8% and 18 ± 5%, respectively, at 30 and 90 minutes after injection in the baseline scans (n = 16). The parent fractions in the naltrexone blocking scans were similar to those from the baseline scans ( Figure 1B) . The estimated metabolite-corrected radioactivity time course in the arterial plasma is shown in Figure 1C . The plasmafree fraction (f P ) of 11 C-LY2795050 was 0.77 ± 0.16% for baseline scans (n = 16) and 0.75 ± 0.16% for blocking scans (n = 16).
Brain Uptake and Kinetics Uptake images from the baseline and naltrexone-blocking scans are shown in Figure 2 . Regional TACs for representative brain regions are shown in Figure 3 .
11 C-LY2795050 displayed favorable imaging properties in the brain, with rapid entry, heterogeneous regional accumulation and fast kinetics. Activity peaked at~4 minutes in all brain regions ( Figures 3A and 3B ). Pretreatment with naltrexone reduced the uptake of the radiotracer in all brain regions, suggesting specific binding of the radiotracer in the brain ( Figures 2C, 3C , and 3D), given the lack of change in the input function ( Figure 1C ).
Kinetic Model Assessment
The baseline scans were used to assess the best model for kinetic analysis. The 1TC and 2TC models reached convergence for every scan in all regions. The mean value of K 1 in the 1TC model ranged from 0.04 mL/cm 3 per minute in the centrum semiovale to 0.11 mL/cm 3 per minute in the occipital cortex. The k 4 value ranged from 0.025 ± 0.003/min (centrum semiovale) to 0.054 ± 0.038/min (cerebellum). The thalamus showed a high k 4 value (0.085 ± 0.031/min).
The 2TC model was favored over the 1TC model according to the AIC and visual assessment of the quality of fits (Figures 3A and  3C ). The F test indicated a significantly better fit for the 2TC model in 223 out of 224 regions. In two cases, the 2TC model provided moderately large V T estimate with large %s.e. Figure S1) . The setting for t* in MA1 had almost no effect on V T estimates (Supplementary Figure S2) for t* ≥ 30 minutes. Note that these comparisons were conducted for the regions with good identifiability, i.e., %s.e. of V T o 10% with the 2TC model.
The V T values derived from 1TC, 2TC, and MA1 model and the minimum scan time for 2TC and MA1 models are shown in Table 1 . High V T values were seen in amygdala, insula, and anterior cingulate cortex. Intermediate V T values were found in globus pallidus, putamen, temporal cortex, frontal cortex, and occipital cortex. Lower V T values were in hippocampus, caudate, posterior cingulate cortex, thalamus, and centrum semiovale, with the lowest V T value in the cerebellum. The intersubject V T variability was low in all models (average of %COV = 10 to 12%). The minimum scan duration was 70 minutes to satisfy all stability criteria in all regions for both 2TC and MA1 models ( Table 1) .
Blocking of Specific Binding by Naltrexone
In all regions, the V T values displayed statistically significant reduction in blocking scans after oral naltrexone (P o0.00001) ( Table 1) , i.e., no region was found that would serve as a reference region. As determined from the occupancy plots (Figure 4) , 150 mg of oral naltrexone occupied 93 ± 6% of specific binding. The nondisplaceable distribution volume (V ND ) for 11 C-LY2795050 was estimated as 1.61 ± 0.25 mL/cm 3 (range: 1.13 to 2.06 mL/cm 3 ). V ND or occupancy values did not have any significant correlation with either gender or subject weight.
The specific binding percentage in the cerebellum ( = (V T CER (baseline) − V ND )/V T CER(baseline) ), the region with the lowest V T , was estimated at 17 ± 10% (range: 4 to 38%), suggesting that cerebellar V T might be a useful estimator of V ND , if corrected. The slope and intercept of the regression line of V ND estimates against cerebellum V T were 1.00 ± 0.29 (95% confidence interval: 0.37 to 1.6) and − 0.34 ± 0.57 (−2.4 to 0.97), respectively. Thus, the intercept was not significantly different from 0 (P = 0.57), and the slope was not significantly different from 1/1.17 (P = 0.63). Thus, we evaluated three approaches to define V ND to calculate binding potentials: (1) individual V ND from the occupancy plot, (2) mean V ND across subjects from the occupancy plots (1.61 mL/cm 3 ), and (3) a fixed fraction of each individual's cerebellum V T (V T CER (baseline) /1.17). Among these three ways to estimate V ND , method (3) provided the lowest intersubject variability in all binding potentials (BP ND , BP P , and BP F ). The binding potential values from MA1 and SRTM with method (3) are summarized in Table 2 . In method (3), the intersubject variability was smallest in BP ND (mean across regions: 22%), followed by BP P (23%), and BP F (30%). For method (2), using the average V ND , variability was substantially higher: BP ND (32%), BP P (32%), and BP F (36%). Using individual V ND values in method (1) produced the highest intersubject variability: BP ND (39%), BP P (28%), and BP F (35%). The corrected BP ND values derived from SRTM were lower than those from the MA1 model (corrected BP ND (SRTM) = 0.89 × corrected BP ND (MA1) +0.06, R 2 = 0.98).
In Vivo Affinity of 11 C-LY2795050
The in vivo BP F values from the present study were correlated with unweighted averages of previously reported regional KOR 4 In the in vitro literature, the unit of specific binding is fmol/mg protein. This unit can be converted to fmol/mg of wet tissue by assuming that there is~0.1 mg protein per mg of wet tissue. 39 A correlation plot of the regional binding potential BP F ( = B avail /K D ) and the in vitro B max is shown in Figure 5 . Figure S3) . In the analysis, the determination coefficient was very low (R 2 o 0.1) with in vitro B max if amygdala, putamen, and globus pallidus measured by 3 H-etrophine are included. Thus, these three regions were excluded from the comparison when using 3 H-etrophine data. Receptor occupancy by the carrier mass of LY2795050 was calculated by 100 × F/(F+K D ), where F is the mean value (from 60 to 90 minutes after injection) of the metabolite-corrected and protein-unbound plasma concentration (expressed in nmol/L), and in vivo K D is assumed to be 0.028 nmol/L (estimated in this study). In all scans, the occupancy by LY2795050 was o 5%. Receptor occupancy estimated using the in vitro K i (0.72 nmol/L) of LY2795050 was even lower. 
DISCUSSION
In this study, we conducted the first-in-human evaluation with the selective KOR antagonist 11 C-LY2795050. Our goals were (1) to determine the optimal model to describe its kinetics, (2) to assess the specific binding component from blocking study with 150 mg of oral naltrexone, and (3) to determine an appropriate method to estimate the nondisplaceable volume of distribution from the blocking data. MA1, multilinear analysis-1; 1TC, one-tissue compartment model; 2TC, two-tissue compartment model. %COV is variability across subjects.
Kinetic modeling of
The metabolism profile of 11 C-LY2795050 in human (44% parent fraction at 30 minutes) was similar to that of rhesus monkey (40% parent fraction at 30 minutes). 17 Similar to the monkey study, 11 C-LY2795050 readily entered into the human brain, and was washed out rapidly ( Figure 3) . The radioactivity in the brain reached peak levels at~4 minutes after injection. This suggests that 11 C-LY2795050 has favorable properties as a radiotracer. The rank order of uptake was also similar to that in the rhesus monkey and consistent with regional KOR densities measured in human postmortem studies in vitro ( Figure 5 ).
The 2TC model 17 and MA1 model with t* = 40 minutes 25 were used as the models of choice for analysis of 11 C-LY2795050 imaging data in rhesus monkeys, with 2TC providing better fits than 1TC. This was also true in humans. The MA1 V T values matched extremely well with those from 2TC. Thus, the 2TC model and MA1 model were selected as suitable models to describe 11 C-LY2795050 kinetics in the human brain. In addition, the t* setting did not have a strong effect on V T estimates (Supplementary Figure S2) . While a late t* value (e.g., 60 minutes) would produce unstable V T estimates due to a smaller number of data points for fitting, MA1 analysis with t* = 30, 40, or 50 minutes all produced reliable V T estimates. One caveat is that the 2TC model in the present human study produced V T estimates with a large standard error in a few cases. Higher levels of noise are usually found in human imaging data compared with those in nonhuman primates, so larger errors in the model parameters are expected. The MA1 model would be more suitable for parametric imaging due to a reasonable computation time. Additional data from more subjects would help with the evaluation of an optimal model for analysis. The values with %s.e.4100% were excluded (n = 10). Note that the instability of k 4 estimation should be considered when discussing a relationship between K D and k 4 values. The centrum semiovale was included in the occupancy plot measurements since its V T was decreased by naltrexone blocking. This blockade was consistent with in vitro data; in the autoradiography study using 3 H-U69593, low density of KOR was detected in the white matter. The occupancy plot relies on the assumption that V ND is the same in all included regions, which could be different in white matter, but in retrospect, the centrum semiovale was not an outlier on occupancy plots. Occupancy and V ND values from the occupancy plots without the centrum semiovale were only 2 ± 1% lower than those with the centrum semiovale included.
In the rhesus monkey study with 11 C-LY2795050, the cerebellum was found to be a suitable reference region, since there was no difference between V T values at baseline and following varying blocking doses of LY2795050. On the other hand, V T values in the present study with naltrexone blocking were significantly reduced in all regions, indicating the lack of an ideal reference region for 11 C-LY2795050 in humans. Therefore, we assessed three methods for the determination of V ND , using intersubject variability of the resulting BP ND , BP P , and BP F as an evaluation and selection criterion.
For all binding potentials, the lowest variability was seen when V ND was estimated as a fraction of the cerebellar V T (method (3)). This suggests that the estimated cerebellum V T correlates with V T estimates for other regions, and therefore the use of the corrected cerebellar V T value as V ND reduces intersubject variability by cancellation of common error or variability. When binding potentials were estimated using individual V ND values derived from occupancy plot of individual subjects (method (1)), high variability in the estimates was found. This is because individual V ND had higher intersubject variability (%COV = 15%) than the fractional cerebellum V T (%COV = 8%). Individual V ND was determined as the x-axis intercept of the occupancy plot (Figure 4) , which is often associated with larger estimation error compared with slope estimation. Interestingly, using the mean V ND (constant value for all subjects, method (2)) yielded binding potential variability that was intermediate between methods (1) and (3), which either suggests that there is true intersubject variability in V ND , or that the cancellation of inherent method-related variability is important. On the basis of these assessments, we chose method (3), i.e., using the fractional cerebellum V T as V ND to estimate binding potentials. In method (3) the binding potential BP ND in the cerebellum is assumed to have a constant value (i.e., α − 1). Thus, the intersubject variability of BP ND in the cerebellum is not taken into account. This approach will be valuable if the specific binding fraction (i.e., BP ND ) in the cerebellum is unchanged by diseases and experimental conditions. We also applied the fractional correction to the BP ND estimates from SRTM. The corrected BP ND values correlated very well with those from the MA1 model, but with an underestimation of~10%.
By correlating BP F values measured here with KOR B max values measured in vitro, we determined an in vivo K D value of 0.028 nmol/L for 11 C-LY2795050 in the human brain. We first compared this value with that obtained in rhesus monkeys. An in vivo ED 50 value of 15.6 μg/kg was derived from a 11 C-LY2795050 PET study with coinjection of unlabeled LY2795050 in rhesus monkey. 25 We calculated the relationship between the injected LY2795050 dose and plasma concentration from the rhesus monkey data used in the paper by Kim et al. 25 To obtain plasma concentration in nmol/L, the measured arterial input functions (Bq/mL) were corrected for protein binding (f P , 0.018 ± 0.002 in rhesus monkeys) and parent fraction, divided by the specific activity of injected 11 C-LY2795050, and then averaged over 40 to 90 minutes after injection of 11 C-LY2795050. Using the regression line (plasma concentration (nmol/L) = 0.0065 × injected dose (μg/kg), R 2 = 0.997, Supplementary Figure S4) , the in vivo ED 50 of LY2795050 was converted to K D (0.10 nmol/L).
The in vivo K D estimates of 0.10 nmol/L in rhesus monkeys and of 0.028 nmol/L (0.019 to 0.056 nmol/L using regional B max values from individual in vitro studies) in humans for 11 C-LY2795050 were smaller than the inhibition coefficient (K i ) of 0.72 nmol/L measured in vitro using cloned human KOR. The discrepancy between in vivo K D values and in vitro K i could be attributed to a number of factors. First, the in vitro K i values are usually determined from radioligand competition assays performed at room temperature (22°C), such as in this case for LY2795050, while in vivo K D values are derived from imaging experiments conducted at body temperature (37°C). Temperature sometimes exerts a significant effect on the binding affinities of radioligands, although the direction of changes is not readily predictable (see Elfving et al 41 ) . For example, the in vitro K i of fallypride for the dopamine D 2 receptor in the rat striatum was 0.04 nmol/L at 22°C and 2.03 nmol/L at 37°C, while the in vivo K D derived from imaging experiments with 18 F-fallypride in baboons was 0.2 nmol/L. 42 For another D 2 ligand IBF, the in vivo K D (0.081 nmol/L for 123 I-IBF) was very similar to the K i measured in vitro at 22°C (0.06 nmol/L) and 37°C (0.10 nmol/L). 43 The benzodiazepine receptor ligand iomazenil is another case in which the in vivo K D (0.54 nmol/L for 123 I-iomazenil) derived from imaging experiments was quite similar to the in vitro K i measures either at 22°C (0.35 nmol/L) or at 37°C (0.66 nmol/L). 44 The uncertainty, or measurement errors in ligand-free fraction in the plasma (f P ), is the second factor that might contribute to the discrepancy between in vivo K D and in vitro K i . f P values are required in the determination of in vivo K D , as they are used to estimate the free ligand concentrations in the brain. In both rhesus monkeys and humans, 11 C-LY2795050 f P was very small (o 2%), and any small errors in its measurement accuracy will contribute to the uncertainty in the K D estimate.
In conclusion, we conducted successfully the first in vivo evaluation of 11 C-LY2795050 in humans. The uptake pattern of 11 C-LY2795050 was in good accordance with the known KOR distribution.
11 C-LY2795050 displayed favorable kinetic properties and can be used for quantitative PET measurement of KOR in human brain. The 2TC and MA1 models were selected as the best model to describe its kinetics and derive binding parameters. Blocking experiments showed that 150 mg of oral naltrexone provided 490% KOR occupancy, and that there was no ideal reference region for 11 C-LY2795050 in the human brain. The use of the cerebellum V T corrected for its small specific binding fraction as V ND was proposed as a method to calculate binding potentials.
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